Abstracts

01 July 12:00 5159.0010

Master program:  Medical Pharmaceutical Sciences
Keywords:  Lipid-Lowering Therapies, Market Access Strategy, Competitor Preparation, Payer Value Proposition
Internship organization:  Daiichi Sankyo Deutschland GmbH
Type of organization: Company
Workplace supervisor: A. (Andrea) Bilgeri
SBP supervisor:  N. (Niels) Alberts-Visscher, MSc
Science supervisor: dr. C.C.M. (Nynke) Schuiling-Veninga
Abstract:  

Cardiovascular diseases (CVDs) are the leading cause of death in Germany and the most costly disease category in the healthcare system. Effective cholesterol management is key to reducing cardiovascular risk, yet many patients do not reach the recommended LDL-C targets.

Daiichi Sankyo Deutschland GmbH (DSDE) has a long history of contributing to advances in lipid-lowering and cardiovascular therapies. As the German lipid-lowering therapy (LLT) market continues to evolve, DSDE is adapting its strategies to ensure its therapies continue to offer value to both payers and patients. Updated clinical guidelines and directives, as well as anticipated introduction of new oral add-on treatment options form challenges and opportunities for DSDE. 

This project looks at the future role and strategic positioning of DSDE from a market access perspective. A combined approach is used, incorporating a scientific literature review, market analysis, insights from interviews with payers and internal stakeholders, and a multi-criteria benefit analysis (MCBA) framework to evaluate the value of current and future treatment options. Real-world evidence (RWE) is also incorporated to improve the understanding of treatment patterns, persistence, and therapy value in routine practice.

The findings will help DSDE to strengthen its market position by creating a clear value proposition that meets the needs of both patients and payers. 

Overall, the project provides valuable insights into how DSDE can adapt to a changing market and develop effective access strategies.

02 July 14:00 5159.0062

Master program: Chemistry
Keywords: Technology readiness and market assessment
Internship organization:  BiomACS B.V.
Type of organization: Company
Workplace supervisor: dr.  R. (Roderick) de Hilster
SBP supervisor:  M.J. (Maarten) van den Nieuwenhof-Schilstra, MSc
Science supervisor: Dr. D. (Dina) Maniar
Abstract:  

Conventional petrochemical plastics have become a ubiquitous solution throughout all aspects of academic and medical research. The overall pipeline of procurement, production, processing, transport, distribution and disposal of conventional plastics hinders the sustainability of research as a result of a high carbon footprint negatively affecting the climate.

This project in particular is concerned with circular plastics researched and developed by BiomACS and its partners. BiomACS is a spin out from UMCG that focuses on innovating in the medical industry via a screening platform for investigating interactions between medical materials and cells in order to arrive at optimal surface properties thereby accelerating the development of advanced medical materials.

The goal of the project is to assess the viability of biodegradable bio-based plastics in the sector of laboratory consumables by examining the performance, financials and production pipelines with respect to conventionally used plastics. Subsequently the capacity for establishing and scaling up production is assessed leading to a development of a strategy to enter and grow in the market along with facilitating a transition towards a circular economy. Establishing and sustaining a circular economy is hindered by the tension between modern sustainability trends and global political volatility necessitating an iterative improvement of infrastructure, a systems-based approach for recycling and a wide network of partners.

The project discusses friction between the market introduction and the industry innovation to answer the following research question: How can BiomACS commercially build and scale up tunable PHA-based laboratory consumables in the health care sector in the Netherlands? 

01 July 15:00 5159.0114

Master program: Computing Science
Keywords: Geospatial Foundation Models, Benchmarking, AI Adoption, Product Positioning
Internship organization: Spheer
Type of organization: Company
Workplace supervisor: J. (Jordy) de Lange, MSc
SBP supervisor: dr. G.A.H. (Gideon) Laugs
Science supervisor:  dr. D. (Daniel) Feitosa
Abstract:  

Geospatial foundation models are becoming powerful tools for extracting patterns from large-scale remote sensing data. However, evaluating their performance in a way that is both scientifically rigorous and meaningful for real-world applications remains challenging. As foundational models are part of larger, interconnected pipelines, they can be difficult to compare in isolation. Instead, benchmarking the entire pipeline provides a structured way to measure performance in different conditions. This kind of context-aware evaluation is especially important for growing companies, where selecting the right models is key to scaling and delivering impact to clients. This project investigates how foundational models can be benchmarked, validated and leveraged to create market value.

In collaboration with Spheer, a geospatial AI company based in Groningen, this work explores benchmarking their foundational model using the PANGAEA benchmarking framework, a standardised pipeline for comparing models across several supported datasets and tasks. The performance results are interpreted to derive clearer insights into the model’s capabilities and limitations. To better understand how the foundational model can be positioned for different clients, these technical insights are combined with relevant business and psychological factors that influence how and why organisations adopt and integrate AI systems in practice. Together, these perspectives are used to advise Spheer on strategic decisions around model positioning, development priorities and client targeting.

Overall, this project brings together technical benchmarking and real-world adoption factors to better understand how geospatial foundation models can create practical value. If you’d like to hear more, feel free to join my presentation on July 1st!

01 July 11:00 5159.0010

Master program: Medical Pharmaceutical Sciences
Keywords: EU Joint Clinical Assessments (EU-JCA), European Health Data Space (EHDS), health technology assessment (HTA), market access Germany, real-world data (RWD)
Internship organization:  Daiichi Sankyo
Type of organization: Company
Workplace supervisor:  dr. B. (Bernhard) Mörtl
SBP supervisor:  M.K. (Mart) van Genne, MSc
Science supervisor: dr. T. (Thea) van Asselt
Abstract:  

The European regulatory landscape for oncology medicines is evolving with the introduction of EU Joint Clinical Assessments (EU-JCA) and the European Health Data Space (EHDS). These initiatives aim to harmonize evidence assessment and enable cross-border health data use, while introducing new considerations for how pharmaceutical companies generate and align evidence across European and national frameworks.

My project, conducted at Daiichi Sankyo Deutschland GmbH within the Health Economics & Outcomes Research and Real-World Data (HEOR&RWD) team in the oncology Value, Access & Pricing department, explores how these developments impact evidence generation and market access strategies in Germany, particularly in the context of the AMNOG dossier process.

By investigating where EU-JCA and AMNOG requirements converge and diverge, and by examining the role of real-world data, my project provides insight into key challenges in evidence planning. In parallel, it examines how the emerging EHDS framework may influence future access to and use of RWD for oncology assessments.

By translating these findings into strategic recommendations and a practical decision-support framework, my project aims to support more efficient evidence strategy and strengthen HTA readiness in an evolving regulatory environment.

02 July 11:00 5159.0114

Master program: Biomedical Sciences
Keywords: Policy for odour nuisance
Internship organization:  GGD Fryslân
Type of organization: Policy organisation
Workplace supervisor: J.C. (Joost) de Bruijn , MSc
SBP supervisor:  drs. M.R. (Michiel) Berger
Science supervisor:  prof. dr.  R. (Robbert) Havekes
Abstract:  

Understanding Industrial Odour Nuisance and Health Impacts in Friesland: Integrating Complaints and Public Health Data 

Industrial odour nuisance is a prevalent environmental issue in Friesland, that can negatively affect quality of life and population health. Despite its relevance, the relationship between reported odour complaints, perceived nuisance and associated health outcomes has not yet been investigated in Friesland. 

This study integrates complaint data from the Fryske Utfieringstsjinst Miljeu en Omjouwing (FUMO) with data on perceived nuisance and health from GGD Fryslân health monitor. A systematic literature review is used to identify determining factors and health effects of odour nuisance. This is combined with spatial and temporal data analysis, to identify patterns and discrepancies between reported complaints and experienced nuisance across Friesland. In addition, a policy analysis is performed to explore suitable policy options for the situation in Friesland. 

Preliminary findings suggest that odour nuisance is not solely determined by measured exposure levels but influenced by contextual and perceptual factors. Expected outcomes include the identification of nuisance hotspots, differences between reported and experienced nuisance and advice on how to integrate these insights into policy. 

This study contributes to a better understanding of the scale and complexity of odour nuisance in Friesland. It highlights the importance of integrating public health data to support evidence-based policy development. If you are interested in this topic, feel free to join the presentation. 

03 July 10:00 5159.0010

Master program: Chemical Engineering
Keywords: Ecolabel, sustainability standards, circularity, waste & resources
Internship organization: Good Environmental Choice Australia (GECA)
Type of organization: Non-governmental organisation
Workplace supervisor: M. (Mark) Barthel, MSc and dr. E. (Elmira) Soghrati
SBP supervisor: M.J. (Maarten) van den Nieuwenhof-Schilstra, MSc
Science supervisor: prof. dr. F. (Francesco) Picchioni
Abstract:  

Translating sustainability goals into auditable standards: An internship at GECA in Australia

Sustainability standards are often used to turn broad environmental goals into practical requirements for companies. However, this is not straightforward. Standards need to reflect scientific evidence and policy goals, but they also need to be clear enough to audit and realistic enough for industry to apply. During my internship at Good Environmental Choice Australia (GECA) in Sydney, I explored how this balance can be achieved in practice within the Australian sustainability and certification context.

GECA is an independent Australian ecolabelling and claims verification organisation. My project focused on how GECA develops and revises standards so that they are scientifically grounded, policy-relevant, auditable, and feasible for industry. To investigate this, I analysed three case studies: waste and resource collection services, recycled products, and specialty cleaning products. I combined literature and policy review with document analysis and organisational analysis to examine how standards are shaped by scientific principles, regulatory drivers, certification requirements, and business realities.

The project shows that the main challenge is not defining sustainability ambitions, but translating them into criteria that work in practice. Across the case studies, recurring tensions appeared between scientific complexity, policy expectations, auditability, and organisational capacity. The result is a set of reflections and recommendations on how GECA can strengthen its standards development process. Join my presentation to discuss what this means for the future of credible and practical sustainability standards and to hear more about my time in Australia!

02 July 10:00 5159.0110

Master program: Biology
Keywords: Rewilding in the Province of Fryslân
Internship organization:  Provincie Fryslân
Type of organization: Policy organisation
Workplace supervisor: L. (Letty) Stupers, MSc
SBP supervisor: drs. M.D.D. (Marlies) Westerhof
Science supervisor: prof. dr.  S. (Simon) Verhulst
Abstract:  

Rewilding is the process of restoring natural processes and creating a complex trophic food web. Its aim is to create a self-sustaining, resilient ecosystem where no to minimal human interference is needed. Various case studies have shown rewilding to be a successful measure to restore ecosystem complexity and biodiversity. Having complex ecosystems with a high biodiversity is important as it creates ecosystem resilience, especially in the context of climate change.

Currenlty, biodiveristy in Fryslân is declining while the costs of nature management are rising. Therefore the Province of Fryslân is interested in exploring whether rewilding strategies could strengthen and complement existing nature management approaches, as well as identifying what the opportunities and challenges are for implementing such strategies. 

I am approaching rewilding as a scale with three levels, ranging from limited intervention to more extensive restoration of natural processes, and connect these to the different nature types the province has. Through scientific research and contact with relevant stakeholders, the opportunities and challenges of implementing these different scales across various nature types have been identified. I will present 3 tables, for each scale of rewilding one, where I will explain the different opportunities rewilding has per naturetype, taking into account the cultural, natura land economic impact. With the goal of aiding the province of Fryslân in taking a cost-effective ecosystem-centred approach to nature management.

02 July 11:00 5159.0062

Master program: Biology
Keywords: Methylation based cancer detection, Entering the US market, Diagnostic start-up, business development, comparison of cervical cancer diagnostic techniques
Internship organization: CC Diagnostics
Type of organization: Company
Workplace supervisor: dr. N (Nutte) van Belzen
SBP supervisor:  dr. M. (Marion) van Rijssel
Science supervisor: prof. dr. F (Frank) Kruyt
Abstract:  

CC Diagnostics has developed a novel methylation-based assay for cervical cancer screening and are planning to launch their product in the US. However, it is unclear what their ideal partner looks like and how to approach them. 

In order to find out how CC Diagnostics can best launch their technology, I created an ideal customer profile, mapped out the decision-making unit to find key roles for outreach and finally how to approach them. I used a PESTEL to access the opportunities and threats in the US market. Finally, I looked at the inner workings of the company and their product to find opportunities and weaknesses and compared this to competitors.

I have helped create a clear picture of what their first customer looks like and how to find them. I also expect to have a clear overview of how CC Diagnostics new product compares to competitive technologies as well as direct competitors also using methylation-based screening. Lastly, I have done interviews with other business developers and created advice on how to enter the US market.

This project will showcase what working as a business developer for a start-up is like, and give insights in how to enter the US market. It also shows what innovation in healthcare looks like from the perspective of an advisor.

I hope to see you all there to delve into and discuss the challenges and opportunities for a diagnostics start-up going to the US!

02 July 10:00 5159.0114

Master program: Biomedical Sciences
Keywords: Optimization of Gezonde School monitoring framework
Internship organization: GGD IJsselland
Type of organization: Policy organisation
Workplace supervisor: M. (Meyke) Faber, MSc & A. (Annelot) van Rooij, MSc
SBP supervisor:  drs. M.R. (Michiel) Berger
Science supervisor: dr. N. (Nynke) Smidt
Abstract:  

For my SBP Master work placement at GGD IJsselland I focus on the monitoring of the “Gezonde School” approach.

Gezonde School is a nationwide initiative that supports schools in embedding physical and mental well-being into their policies and teaching, making healthy choices the easy and obvious choice for students.

Current trends indicate deteriorating physical and mental health among young people, driven by increasingly prevalent lifestyle-related risk factors. That is why effective prevention strategies are essential to improve population health outcomes and increase healthy life expectancy. This is not only important for the health of the youth, but also from an economic perspective. By investing in addressing health determinants early, we avoid high future costs in chronic disease management and specialized care.

Using a stakeholder-oriented approach, I analyze the needs of schools, municipalities, and GGD advisors through semi-structured interviews to optimize the monitoring of the Gezonde School approach. Preliminary findings indicate fragmentation in monitoring practices across GGD regions, as well as variability in collaboration with youth healthcare services (JGZ). Additionally, stakeholders express a need to better utilize existing data sources to assess the impact of Gezonde School, while avoiding additional administrative burden on schools.

My goal is to provide practical recommendations that support the continued development and impact of this approach.

If you are interested in this topic and would like to learn more about practical experiences from a public health work placement, I invite you to attend my presentation.

03 July 10:00 5159.0062

Master program: Marine Biology
Keywords: Diagnostics for the future of aquaculture
Internship organization: Wageningen Bio-Veterinary Research Institute
Type of organization: Research Institution
Workplace supervisor: dr. ir. M (Marc) Engelsma
SBP supervisor: dr. M.K. (Karin) de Boer
Science supervisor: prof. dr. S. (Sancia) van der Meij
Abstract:  

With a globally expanding industry of aquaculture to meet rising demands for human and animal consumption, ornamental hobbyists, and environmental restoration, there is increasing need to ensure the health of the kept populations. Aeromonas salmonicida is a globally recognised virulent bacterium predominately affecting salmonids, although there is emergence of atypical strains affecting non-salmonid hosts. The Wageningen Bio-Veterinary Research Institute (WBVR) is at the forefront of diagnostic responsibilities and research for agricultural and aquacultural animal diseases here in the Netherlands.. 

WBVR strives to ensure that they are exploring new possibilities for more accurate and efficient diagnostics. My project focuses on past, current, and emerging diagnostic techniques for this bacterium, as well as evaluating which levels of resulting information are most relevant for each client. The introduction of mandatory antimicrobial reporting for selected finfish species in aquaculture facilities under an EU directive from 2027 expands the project to include antimicrobial resistance in this bacterium and advice for how the directive might influence future policy. The goal is to create a better understanding of what is needed in terms of diagnostics for stakeholders when it comes to this bacterium.

All of this better pushes forward the ongoing role WBVR plays in both expanding research and diagnostic techniques to ensure the health of the significant agricultural and aquacultural species. 

If you are interested in the diagnostic work and learning more about the role they play in the health of cultured animals and policy, come and see my presentation!

01 July 14:00 5159.0110

Master program: Biomedical Sciences
Keywords: Strengthening Operational Efficiency in a Clinical Research Organization
Internship organization: TRACER
Type of organization: Company
Workplace supervisor: F. (Famke) van Renesse-Brouwer, MSc
SBP supervisor: P.C. (Pieter) Vogelaar, MSc
Science supervisor: prof. dr. G. (Geert) van den Bogaart
Abstract:  

Drug development is a complex, time-consuming, and costly process. Clinical Research Organizations (CROs) play a key role by managing early phase clinical trials for pharmaceutical sponsors. Ensuring consistent quality and timely delivery of clinical studies is essential for a CRO. TRACER, a CRO specializing in nuclear imaging services for early-phase trials (Phase 0-2) is currently growing as a company, bringing higher expectations by large pharma and biotech companies. This project therefore examines how TRACER’s operational efficiency can be increased through process optimization and effective stakeholder management. 

The project integrates scientific insights with an evaluation of internal processes and external stakeholder dynamics. Analysis of the regulatory framework and stakeholder environment will highlight how external factors shape daily operations. Understanding the complex regulations and operations behind the use of radioactive investigational drugs in clinical trials is crucial to understand how the external environment shapes daily operations. Interviews with the clinical team mapped processes, roles, responsibilities, and timelines, revealing operational bottlenecks. Together with McKinsey’s 7S analysis, this identified opportunities for optimization and informed the development of a standardized, visual overview of the processes. Additionally, Porter’s 5 Forces was used to assess the competitive landscape and position of stakeholders.  

By linking scientific and operational factors that are critical for the succesful execution of clinical trials with stakeholder dynamics, the project identifies areas that need closer management and optimization. The findings emphasize that strong communiation skills, flexibility, and clear agreements between stakeholders are essential for efficient operations, leading to practical recommendations to improve the performance of a CRO. 

Want to know more? Join my presentation! 

02 July 13:00 5159.267

Master program: Biomedical Sciences
Keywords: Pre-launch strategy for rare diseases
Internship organization: AstraZeneca
Type of organization: Company
Workplace supervisor: T. (Tobias) Nederkoorn, MSc
SBP supervisor:  M.K. (Mart) van Genne, MSc
Science supervisor: prof. dr. G. (Geert) van den Bogaart
Abstract:  

The introduction of innovative therapies requires careful medical and organisational preparation to ensure alignment with healthcare systems and medical needs. During this internship at AstraZeneca (Medical Affairs), I support medical and commercial activities related to early market preparation for a new treatment targeting a rare disease, with a specific emphasis on the Dutch healthcare environment.

This project adopts a mixed qualitative and desk research approach aimed at gaining insight into the structure and functioning of the healthcare landscape. Key activities include analysing relevant healthcare policies, referral pathways, and stakeholder roles, as well as mapping care pathways to better understand how patients move through the healthcare system. These analyses are complemented by the review of publicly available information sources and internal and external expert discussions. 

Preliminary findings highlight substantial variability in disease recognition and referral pathways, contributing to delays in diagnosis and treatment initiation. By systematically mapping these structures and gathering medical insights, the project provides a structured overview of key considerations relevant for pre-launch strategies. 

This project demonstrates how integrating medical, market, and healthcare system perspectives can contribute to more effective access strategies for rare disease therapies. What made this experience particularly rewarding is the close collaboration with cross-functional teams and knowing my work will ultimately make a real impact on patients' lives.

Join the presentation to explore the project findings in more detail and to discuss my experiences and learnings from working within Medical Affairs at a pharmaceutical company. See you there!

02 July 13:00 5159.0114

Master program: Biomedical Sciences
Keywords: skin cancer, primary schools, prevention
Internship organization:  GGD Fryslân
Type of organization: Policy organisation
Workplace supervisor: I. (Ike) Hutter , MSc
SBP supervisor:  drs. M.R. (Michiel) Berger
Science supervisor: prof. dr. F.A.E. (Frank) Kruyt
Abstract:  

If nothing changes, the percentage of skin cancer diagnoses will increase with 33% in the Netherlands from 2022 to 2032. To get this number to drop, action needs to be taken. This can be done by changing the behavior of primary school children by getting them to be more protective in sun protection. This is where the project ‘Weren, Kleren, Smeren’ kicks in. 

Since its launch in 2024, participating primary schools have received sunscreen dispensers, shade cloths, and educational materials. The long-term aim is to structurally embed sun protection into school policies, ensuring sustainable attention to this topic.

This study evaluates the implementation of the project at its halfway point. Data are collected through interviews with school staff involved in the project. Preliminary findings show that awareness of sun protection has increased, but implementation remains inconsistent. Barriers include limited prioritization, varying levels of engagement among staff and parents, and a lack of formal policy integration.

Based on these findings, recommendations are formulated on two levels: (1) how the GGD can better support schools in strengthening implementation, and (2) which additional steps are needed to encourage consistent sun-safe behavior among children, staff, and parents.

Are you interested in learning which steps are still needed to improve sun protection in schools? Join my presentation!

02 July 11:00 5159.0010

Master program: Biomedical Sciences
Keywords: Evidence Generation Planning, Patient Perspective
Internship organization: Asc Academics
Type of organization: Company
Workplace supervisor: S. (Stan) Huisman, MSc
SBP supervisor:  P.C. (Pieter) Vogelaar, MSc
Science supervisor: prof. dr. R.P. (Rob) Coppes
Abstract:  

Evidence generation is central to successful drug development and market access. Beyond demonstrating clinical efficacy and safety data, developers must provide real-world evidence, economic value, patient-centred outcomes, and information aligned with regulator and Health Technology Assessment (HTA) expectations. A structured Evidence Generation Plan (EGP) enables developers to define a coherent evidence strategy across the full product lifecycle, ensuring that data collection is purposeful, timely, safes costs, and aligns with current and future regulatory and reimbursement needs. Patient perspectives are increasingly recognised by regulators and HTA bodies as important evidence inputs. Patient perspectives can be relevant across the entire product life cycle, from early target identification and endpoint selection to HEOR analyses and real-world evidence generation after launch. Despite this, many organisations still struggle to operationalise patient involvement, determine which methods to use, and to see the value and actual impact of patient-centric initiatives. 

Asc Academics is a health economics and outcomes research (HEOR), and market access consultancy based in Groningen. They have requested me to identify evidence requirements along the product lifecycle, develop an EGP, gain a deeper understanding of the value of patient perspective and evaluate if an EGP incorporating patient perspective would be a potential new service they could offer. The EGP and patient perspective methodologies will be demonstrated based on a prostate cancer case study. 

If you are interested in learning more about evidence generation and the importance of patient perspective, feel free to join my presentation at the SBP conference! 

01 July 12:00 5159.0110

Master program: Biomedical Sciences
Keywords: Clinical relevance assessment new medication for Dutch reimbursement
Internship organization: AstraZeneca
Type of organization: Company
Workplace supervisor: S. (Susanne) Nekeman, MSc
SBP supervisor:  J. (Jorien) Zevenberg, MSc
Science supervisor: prof. dr. F. (Frank) Kruyt
Abstract:  

This internship project explores how past reimbursement advice from Zorginstituut Nederland (ZIN) can provide insight into the assessment of clinical relevance in the Dutch healthcare system. Understanding this process is important, because such assessments play a key role in determining whether innovative medicines become available to patients through reimbursement. The project is conducted at AstraZeneca and spends particular attention to the criteria that are used, the type of evidence and the scientific background of the treatment and indication that appear in the advice. This approach helps to build a clearer picture of how reimbursement decisions are shaped in practice within the Netherlands. The findings so far suggest that the assessment of clinical relevance of new treatments involves more than clinical trial outcomes alone. ZIN’s recommendations appear to reflect a broader interpretation of value, in which multiple dimensions of evidence and context are brought together. This makes the project relevant not only for market access practice, but also for the broader field of science-based policy, as it highlights the intersection of biomedical innovation, decision-making, and patient access. Join my presentation to learn more about this topic!

01 July 12:00 5159.0291

Master program: Biomedical Sciences
Keywords: Advisory Model Development, Drug Development Consultancy, Academic Drug Discovery, Early-Stage Drug Development, Neurodegenerative Diseases
Internship organization:  3D-PharmXchange
Type of organization: Company
Workplace supervisor: O. (Oscar) Loosbroek, MSc
SBP supervisor:  M.K. (Mart) van Genne, MSc
Science supervisor: prof. U.L.M (Ulrich) Eisel
Abstract:  

In drug discovery, many promising therapeutic ideas originate in academia. However, translating these early-stage discoveries into viable drug development programs remains a major challenge, particularly in complex fields such as neurodegenerative diseases. Academic projects often face uncertainties related to development strategy, funding pathways, and alignment with industry and regulatory expectations, limiting their progression toward clinical and commercial application.

This project is conducted at 3D-PharmXchange, a drug development consultancy that supports biotech, pharmaceutical, and academic organisations. As the company increasingly works with early-stage academic clients, there is a need to further structure its advisory approach to address the specific challenges of this client group.

The aim of this project was to investigate and formulate a structured advisory model for 3D-PharmXchange to effectively support early-stage academic drug discovery projects.

To achieve this, I combined literature research on the neurodegenerative drug development landscape and the needs of early-stage academic clients with analysis of internal consultancy practices, stakeholder interviews, and benchmarking of competitor approaches. In parallel, I contributed to an ongoing consultancy project for one of 3D-PharmXchange’s academic clients in the field of Alzheimer’s disease, where I applied 3D-PharmXchange’s existing advisory tools and approaches. This enabled the identification of strengths, limitations, and gaps in the current advisory approach within a real-world academic client setting.

Altogether, these findings support the development of a more structured and effective advisory approach, strengthening 3D-PharmXchange’s ability to support this emerging client group. If you are curious to hear about the results and want to learn more about consultancy, then join my presentation!

02 July 13:00 5159.0010

Master program: Biomedical Sciences
Keywords: Patient Perspectives in Health Economic Modelling
Internship organization: Asc Academics
Type of organization: Company
Workplace supervisor: J. (Jet) Neervoort, MSc
SBP supervisor: P.C. (Pieter) Vogelaar, MSc
Science supervisor: prof. dr. E.A. (Eddy) van der Zee
Abstract:  

Patient needs are increasingly recognised as a critical dimension of healthcare, reshaping how we evaluate new treatments. Health economic modelling plays a key role in reimbursement decisions by demonstrating the cost-effectiveness of a treatment. Asc Academics is a consultancy that supports their clients in this process by developing health economic models that communicate the value of their product. 

This project explores how Asc Academics can strengthen the patient centricity of its modelling practice. The work uses a dual approach with a review of emerging methods that aim to integrate patient centred value into economic evaluations, and interviews with involved stakeholders. This combination helps to identify future modelling standards, what types of data are needed, and how expectations differ across stakeholders who rely on these models. Because patient needs vary widely across conditions, multiple sclerosis is used as a case study to illustrate disease specific challenges and opportunities for incorporating patient generated evidence.

Findings show a desire among stakeholders for models that move beyond narrow effectiveness measures to include broader patient focused value. At the same time, practical methods to translate these insights into modelling remain limited, creating both uncertainty and opportunity. This evolving landscape positions Asc Academics to contribute to shaping more patient centred modelling standards.

Strengthening the patient focus of economic models ultimately supports decisions that enable patients to access the care they genuinely need.

If you are interested in discussing this work, I would be happy  to connect during the conference.

01 July 11:00 5159.0110

Master program: Energy & Environmental Sciences
Keywords: Corrosion mitigation in CO2 transport
Internship organization: Nederlandse Gasunie N.V.
Type of organization: Company, state-owned
Workplace supervisor:  dr. M.T. (Menno) van Os & M. (Martin) van Agteren, MSc
SBP supervisor:  dr. G.A.H. (Gideon) Laugs
Science supervisor: prof. dr. F. (Franco) Ruzzenenti
Abstract:  

Carbon capture and storage (CCS) is an essential method for decarbonization in the global energy transition. Gasunie, the state-owned energy transport operator of the Netherlands, already has CCS projects underway, and are planning to expand in the future to become a large player in commercial carbon dioxide transport in Europe. Large-scale transport of CO2, however, comes with challenges, such as the formation of acids, which leads to corrosion of steel pipelines. In my project, I dive into the mechanisms behind this corrosion and consider options to address this problem, using findings from literature and input from various experts in the field. Additionally, I consider the value of possible solutions in the CCS chain, as effective methods could reduce the need for CO2 purification, and consider their impact in the broader context of the energy transition. Findings so far indicate various potential solutions, such as scavenger molecules which react with impurities to prevent acid formation, or internal coatings, which can act as barriers to protect the pipeline from acids. Their application in future projects, however, still comes with technical questions, which I aim to address. Corrosion in CCS is one of the main problems which limit large-scale, commercial CO2 transport, and I am excited to contribute to a solution and strengthen Gasunie’s position in the future CCS market. If you are as interested as I am in the energy transition, and in how a state-owned energy transport operator tackles technical challenges in commercial avenues, join the conversation at my talk at the SBP conference. 

02 July 10:00 5159.0267

Master program: Biomedical Sciences
Keywords: Discrete-event simulation in health economics
Internship organization: Asc Academics
Type of organization: Company
Workplace supervisor: T. (Tjeerd) Looman, MSc
SBP supervisor: M.K. (Mart) van Genne, MSc
Science supervisor: dr. I. H. (Iris) Jonkers
Abstract:  

Health economic models play a central role in informing reimbursement decisions, yet increasing clinical complexity challenges the suitability of commonly used modelling approaches. In particular, diseases such as breast cancer are characterised by heterogeneous patient populations, sequential treatment pathways, and time-dependent events, which may be difficult to capture using traditional cohort-based models such as Markov or partitioned survival models.

This report assesses whether discrete-event simulation (DES) should be integrated into health economic modelling practice. To support this assessment, the report first reviews existing economic modelling approaches and introduces DES as an alternative framework. This is followed by an analysis of current modelling methodologies and their practical limitations in the context of health technology assessment.

The applicability of DES is then explored using breast cancer as a case study, focusing on modelling challenges arising from complex care pathways and evaluating the potential advantages and limitations of DES in this context. In addition, an investment assessment and a strategic analysis are conducted to evaluate the feasibility of DES and to establish the circumstances under which it provides added value.

Based on these components, the report provides structured advice regarding the potential integration of DES, including conditions for use and implementation consideration from a methodological and strategic perspective.

01 July 12:00 5159.0062

Master program: Biomedical Sciences
Keywords: Reimbursement, medical devices, critical care
Internship organization: ParaMedir
Type of organization: Company
Workplace supervisor: N. (Nura) Serelkhatim, MSc
SBP supervisor: P.C. (Pieter) Vogelaar, MSc
Science supervisor: prof. dr. P. (Peter) Heeringa
Abstract:  

This project explores the criteria and clinical evidence required to secure reimbursement of the UriMoni®, a low-risk in vitro diagnostic device used to measure urine biomarkers for patient monitoring. The main aim is to provide strategic recommendations for ParaMedir to obtain reimbursement for this innovative device based on a comparative analysis of the reimbursement landscapes in six key European target markets. 

Reimbursement is essential in healthcare as it ensures payers and providers are compensated for medical products and services offered. It ensures that innovative health technologies are accessible and affordable for both healthcare systems and patients, and supports sustainability and profitability for manufacturers. Navigating reimbursement requirements in multiple markets is complex due to differing stakeholder involvement, expectations, and priorities.

An overview of the structures and pathways to reimbursement across six key European target markets was developed and used to perform a gap analysis comparing the clinical evidence requirements in each market. Additionally, a clinical value assessment was conducted to highlight unmet clinical needs in the diagnosis, treatment, and monitoring of patients in critical care, particularly for the use cases of acute kidney injury and acute heart failure. The aim of this assessment was also to explore how UriMoni® could address these gaps and provide clinical benefit in this context as demonstrating this value is essential for securing hospital reimbursement and adoption.  

These findings, in conjunction with an internal analysis of ParaMedir’s organisational structures, resources, and capabilities, were used to generate a strategy aimed at achieving adoption and reimbursement of UriMoni® in Europe.

02 July 14:00 5159.0114

Master program: Energy & Environmental Sciences
Keywords: Long-duration energy storage, LDES, Multi-criteria analysis, Multi-level perspective, energy storage, window-of-opportunity
Internship organization: Enerzien
Type of organization: Company
Workplace supervisor: I. Meijers, MSc
SBP supervisor:  dr. G.A.H. (Gideon) Laugs
Science supervisor: dr. X. Sun
Abstract:  

My name is Guus Borger and I am currently doing my SBP-internship at Enerzien, an energy consultancy based in Amsterdam.

As we transition towards a renewable energy system, the share of solar and wind energy is growing rapidly. With this development comes an issue, since our methods to store this energy are currently limited and these sources of renewable electricity generation are intermittent. Therefore, I am looking into ways to store renewable energy through long-duration energy storage (LDES) methods, a technology branch expected to proof vital to our energy security in the coming decades. With the goal to provide Enerzien with executable, attractive business opportunities with regards to LDES. 

Through interviews with experts and colleagues, as well as, literature research, I am mapping the different LDES. Synthesizing the relevant information into a multi-criteria analysis that allows for identification of the most promising options from a technical perspective. Combining these insights with how the problem context and external context are evolving, a window-of-opportunity for development of LDES is identified. Together with the capabilities and resources of Enerzien, a fitting strategy is proposed.  

This project has continuously been challenging me to bridge scientific analysis with strategic business thinking. I believe bridging these ways of thinking will be vital to the challenges we face in the energy transition. 

At the SBP-Conference I will be presenting my findings with a future where LDES will play an important role in our energy system. I hope to see you there and discuss my findings together!

01 July 15:00 5159.0062

Master program: Biomedical Sciences
Keywords: Market strategy for sustainable biotech
Internship organization: Stichting Business Generator Groningen
Type of organization: Company
Workplace supervisor: R.M. (Ronja) Wabeke, MSc
SBP supervisor: M.J. (Maarten) van den Nieuwenhof-Schilstra, MSc
Science supervisor: prof. dr. G. (Gertjan) van Dijk
Abstract:  

I am doing my internship at Stichting Business Generator Groningen, where they support researchers from the University of Groningen and the UMCG in the valorisation of their research. 

Here, I am contributing to the development of the go-to-market strategy for MycoSafe. MycoSafe is a pre-start-up developing yeast-derived antifungal proteins designed to prevent fungal spoilage in food, beverages, and agriculture.

By offering a natural, safe, and sustainable alternative to chemical preservatives and energy-intensive processing methods, this innovation has the potential to make food systems and agricultural practices more sustainable.

As part of my internship, I am researching the market, mapping key stakeholders, identifying customer needs, and analyzing the competitive landscape. These insights will help shape the tailored go-to-market strategy for MycoSafe

If you're interested in MycoSafe, its potential applications, or my research, feel free to join my presentation for further information and a deeper discussion!

Master program: Biomedical Sciences
Keywords: Socioeconomic status, COPD, collaborative care, impact evaluation service
Internship organization:  ZorgfocuZ B.V.
Type of organization: Company
Workplace supervisor: W. Dam, MSc. & dr. V. Boswijk
SBP supervisor: drs. M.D.D. (Marlies) Westerhof
Science supervisor: dr. N. (Nynke) Smidt
Abstract:  

Socioeconomic health disparities continue to represent a major challenge in Dutch society, with COPD forming a prime example of a disease which is 2-3 times more prevalent in populations with low socioeconomic status than in populations with high socioeconomic status. Treating these patients typically requires a combination of multi-disciplinary therapies at the intersection of the medical and social domain. However, collaboration between professionals from both domains is often limited, leading to ineffective and inefficient patient care. Consequently, the Dutch national government published a guideline aimed at improving patient health outcomes through striving for enhanced medical-social collaborations.

As a research and consultancy office, ZorgfocuZ has been asked to assess whether these collaborations actually have an effect. This is why my project is focused on developing an impact evaluation framework for assessing the effects of stronger medical-social collaborations on the health outcomes of COPD patients with low socioeconomic status. This novel framework is constructed based on literature research and is tailored to the context of COPD and low socioeconomic status. Ultimately, this framework will enable ZorgfocuZ to offer an evidence-based evaluation service to clients, supporting efforts to reduce health inequities.

Main findings highlight the importance of smooth referral and patient education in improving patient health outcomes. By developing a robust tool for assessing collaboration impact, this project aims to contribute to reducing socioeconomic health disparities in the Netherlands.

Feel free to join my presentation to explore how impact evaluation can address socioeconomic health differences and discuss the framework’s potential applications!

02 July 10:00 5159.0062

Master program: Physics
Keywords: Simulations, robotics, magnetism, medical devices, R&D
Internship organization: Flux Robotics
Type of organization: Company
Workplace supervisor: W. (Wimold) Peters, MEng
SBP supervisor: dr. G.A.H. (Gideon) Laugs
Science supervisor: dr. P.G. (Peter) Dendooven
Abstract:  

Medical robotics is a booming industry at the forefront of modern healthcare innovation. By integrating new technologies it makes surgeries less invasive, safer and more efficient.

Flux Robotics is a pioneering start-up in this field, it is developing a magnetic navigation system for endovascular surgeries. This technology would reduce procedure times, vessel damage, and radiation exposure.

This project addresses two objectives. The first focuses on optimizing the robot’s magnetic head using computational models to refine its shape and design parameters. The second objective evaluates the methodology itself, and its added value to the design process and company workflow.

The central research question explores how simulation techniques can benefit Flux Robotics. By assessing both the technical and strategic implications, the project aims to determine whether investment in some simulation software is justified.

02 July 13:00 5159.0110

Master program: Biology
Keywords: light pollution, artificial light at night (ALAN), biodiversity & ecosystems, human health, municipal policy, dark skies, public lighting
Internship organization: de Natuur en Milieufederaties
Type of organization: Non-profit foundation
Workplace supervisor: N. (Nynke) Visser, MSc
SBP supervisor: drs. M.D.D. (Marlies) Westerhof
Science supervisor: K.J. (Koen) van Benthem, PhD
Abstract:  

The excessive and misdirected use of artificial light at night has led to the increasingly urgent environmental challenge of light pollution. While artificial light enables social and economic activity at night, it also has well-documented impacts on human health, biodiversity, energy use and the cultural experience of dark night skies. At the same time, it raises important questions about safety and the role of lighting in public space. Despite growing scientific evidence and awareness, effective policy action to reduce light pollution remains limited, particularly in the Netherlands, which is among the most light-polluted countries. In this context, my project investigates how scientific knowledge on light pollution can be effectively translated into actionable policy guidance for Dutch municipalities. Conducted within the ‘Nacht van de Nacht’ programme of the Dutch Natuur en Milieufederaties, the project focuses on developing a ‘darkening’ guideline to support municipalities in making smarter lighting decisions. This involves integrating scientific literature, policy and governance analysis and expert interviews. Preliminary findings indicate that the primary challenge is not a lack of knowledge, but the difficulty of sharing and translating this knowledge into action in a complex and sensitive policy context, where safety, sustainability and differing interests must be carefully balanced. In doing so, reducing light pollution can contribute to health, nature and safe public spaces. Attendees are welcome to join my presentation to explore how light pollution can be addressed through integrated, actionable policy solutions.

01 July 15:00 5159.0010

Master program: Medical Pharmaceutical Sciences
Keywords: HEOR, Market Access, early Health Technology Assessment, Antimicrobial Resistance (AMR)
Internship organization: DRAiGON Consortium, Health-Ecore
Type of organization: Consortium
Workplace supervisor: dr. Simon van der Pol
SBP supervisor: N. (Niels) Alberts-Visscher, MSc
Science supervisor: prof. dr. T.L. (Talitha) Feenstra
Abstract:  

Antimicrobial resistance (AMR) is one of the greatest threats to modern healthcare systems; fast and accurate diagnostics are a cornerstone of antimicrobial stewardship, enabling timely and appropriate treatment while limiting antibiotic misuse. However, current technologies typically require 24–72 hours after blood culture initiation to deliver reliable results. During this period, patients are treated empirically with broad-spectrum antibiotics, later refined once pathogen identification and antibiotic susceptibility profiles (AST) become available. This delay contributes to AMR by increasing selective pressure on pathogens and facilitating the emergence of resistant strains, while also leading to inefficient use of healthcare resources.

Innovative solutions for rapid and accurate diagnostics are therefore essential. The DRAiGON Consortium aims to address these challenges by developing an AI-supported diagnostic tool capable of delivering “the right antibiotic, for the right infection, at the right time.” This thesis was conducted in collaboration with Health-Ecore, a DRAiGON partner leading the related health technology assessment (HTA) activities.

As the diagnostic tool is in an early stage of development, this thesis evaluates its potential clinical, health-economic, and commercial value in the context of bloodstream infection (BSI) diagnosis within the Dutch and European setting. This is achieved through an early HTA framework, incorporating key model parameters, strategic business analysis, and an assessment of competing technologies and regulatory requirements.

The findings aim to inform the Consortium on the technology’s potential, key uncertainties, and evidence gaps, supporting strategic decisions on further development, research priorities, and investment planning, potentially strengthening the fight for AMR.

03 July 12:00 5159.0010

Master program: Biomedical Sciences
Keywords: Wildswimming, risk-analysis, aquatic pathogens, water-management
Internship organization:  Provincie Overijssel
Type of organization: Policy organisation
Workplace supervisor: S. (Sybren) Osinga, dr. V. (Valesca) Harezlak
SBP supervisor:  M.J. (Maarten) van den Nieuwenhof-Schilstra, MSc
Science supervisor: prof. dr. J.M. (Jan Maarten) van Dijl
Abstract:  

Within the province of Overijssel, water-recreation and swimming in open waters is a popular activity among both residents and tourists, and has a positive impact on public health, social cohesion, mental wellbeing, and the local economy.

However, water-recreation can also come with various risks which can originate from physical, chemical or microbiological factors. To protect swimmers against such risks, the provincial government, along with other (local) governments, has to officially designate swimming sites or take other measures where a high number of swimmers is expected according to the European bathing water directive. When officially designating a swimming site, physical measures are being taken and the water quality is being monitored.

If designating is not possible due to safety concerns, the provincial government can issue a negative swimming advice or can prohibit swimming in some cases. Yet, ‘wildswimming’  at these unofficial swimming sites may still occur. Since there are no protective measures being taken here, wildswimmers may be exposed to certain pathogens, possibly leading to (serious) unforeseen health consequences.

As a result, the provincial government strongly advises to only swim in areas that are officially designated. However, it is not always clear what the risks could be, if wildswimmers are aware of these risks, and what responsibilities (local) governments have. Therefore, the province of Overijssel asked for an overview of the pathogenic risks that are associated with wildswimming, and to find appropriate policy measures based on these identified risks by diving in the complexity of the associated pathogens and water-management.

03 July 12:00 5159.0114

Master program: Biology
Keywords: Government market opportunities, renewable energy policy, anaerobic digestion, provincial governance
Internship organization:  Bioclear Earth
Type of organization: Company
Workplace supervisor: J.(Jeroen) Tideman,  MSc
SBP supervisor:  dr. G.A.H. (Gideon) Laugs
Science supervisor: prof. dr. G.J.W. (Gert-Jan) Euverink
Abstract:  

My internship takes place at Bioclear Earth (BCE), a consultancy company that focuses on sustainable solutions regarding bioenergy, soil, and water. My project explores bioenergy opportunities for BCE in provincial governments, concerning anaerobic digestion and its products biogas and digestate. 

Anaerobic digestion is a process in which microorganisms break down organic waste streams (such as agricultural waste and manure), in the absence of oxygen. This produces biogas, which can be upgraded into a renewable energy source, and digestate, a nutrient-rich byproduct with potential as a fertiliser, though its use also involves regulatory considerations. 

My project focuses on building an picture of provincial involvement in this topic. I combine desk research with stakeholder interviews to map key challenges, active policy initiatives, relevant stakeholders, and provincial characteristics. At the same time I am conducting an internal analysis to assess the potential role BCE can play as a consultant for the provinces. 

What my findings so far reveal is that there are rarely straightforward answers. The role provinces take on differs, motivations vary, and not every province sees the same potential in anaerobic digestion. This will also mean that the role BCE could take on within the different provinces will differ. The many stakeholders and competing interests involved often make progress toward sustainable solutions challenging, which is exactly why it’s such an interesting area to look into. 

If you want to know more about my project, please feel welcome to come to my presentation!

01 July 15:00 5159.0291

Master program: Biomedical Sciences
Keywords: Caesarian Section, Biological Safety, Medical Device, Regulatory
Internship organization:  NUA Surgical
Type of organization: Company
Workplace supervisor: B. (Barry) McCann, MSc
SBP supervisor:  dr. M. (Marion) van Rijssel
Science supervisor: dr. R. (Romana) Schirhagl
Abstract:  

Caesarean section (CS) is one of the most frequently performed surgical procedures worldwide and the most common major operation in many countries. Over recent decades, CS rates have risen steadily, exceeding the population-based thresholds recommended by the World Health Organization. Although performed routinely, CS carries risks including infection, haemorrhage, thromboembolism, anaesthetic complications, and, in rare cases, maternal death.

Despite its widespread use, surgical techniques and tools vary considerably, with no internationally recognised standard approach. Furthermore, key elements of the procedure still rely on traditional manual techniques and rigid retraction systems originally designed for general abdominal surgery, rather than being specifically optimised for obstetric care.

NUA Surgical is a MedTech start-up company based in Galway, Ireland that is dedicated to advancing women’s health by addressing unmet clinical needs in obstetrics and gynaecology. In response to the lack of innovation and clear clinical need, NUA Surgical have developed their inaugural device; the SteriCISION C-Section Retractor. SteriCISION is a self-retaining retractor specifically designed for use in CS surgery. Currently, NUA Surgical is in the pre-clinical development phase of this device and is progressing towards regulatory submission. 

As part of this process, my role has involved researching the specific requirements necessary to demonstrate the biological safety of this device. My project provides NUA Surgical with a strategic pathway for biological safety testing that aligns with regulatory expectations and supports an efficient and streamlined market approval process. To develop my final recommendations, I have analysed biological safety regulatory frameworks across key jurisdictions, including the United States and the European Union, and highlighted critical differences between them. I also assessed the company’s internal capabilities for biological safety testing and identified current emerging trends in the field. Based on these insights, I have proposed a strategy for a robust and future-proof biological safety plan that aligns with the company’s needs, capacities, and future objectives.

If you would like to learn more about my project, please feel free to join my presentation!

01 July 11:00 5159.0114

Master program: Biomedical Sciences
Keywords: Preventative Care, Early Intervention, Parental Resilience, First 1000 days, Kansrijke Start, Kansrijk Opgroeien
Internship organization: Friese Preventie Aanpak (FPA) / GGD Fryslân
Type of organization: Policy organisation
Workplace supervisor: A.T. (Albertine) Visbeek, MSc
SBP supervisor:  drs. M.R. (Michiel) Berger
Science supervisor: prof. dr. J.D.A. (Jocelien) Olivier
Abstract:  

Strengthen resilience through a shared regional preventative approach in Friesland

In Friesland, families increasingly experience challenges related to financial strain, reduced social support, and rising expectations. These pressures contribute to a growing demand for youthcare services. Strengthening resilience through preventative measures and coherent support systems is therefore essential. The Friese Preventie Aanpak (FPA), the regional prevention infrastructure of Friesland, plays a role in guiding municipalities toward integrated and effective preventative strategies.

This study examines how a shared regional approach can enhance the organization of preventative family support and reduce fragmentation between professionals. Using a qualitative methodology, the research combines scientific and policy literature, deskresearch, and interviews with professionals from public health, policy, and youth care. Existing preventative initiatives are analyzed to identify gaps, overlaps and inconcistencies in support across key developmental stages from preconception to adolescence

Early findings indicate that while many effective initiatives exist, preventative support for children and parents is often fragmented. Professionals reported a lack of overview, shared terminology, and continuity across the care chain. These challenges emphasize the need for a collective vision and cohered framework. 

The study aims to the development of Gezinskompas Fryslân, a shared regional guide designed to stimulate integrated, preventative policies for families from pregnancy (-9 months) up to 19 years old. 

Those interested are invited to join the final conference presentation to explore findings and potential next steps!

02 July 13:00 5159.0062

Master program: Biomedical Sciences
Keywords: UMCG rare disease patient data (re)use
Internship organization: UMCG
Type of organization: Policy organisation
Workplace supervisor: dr. T.G.J. (Terry) Derks
SBP supervisor: dr. M. (Marion) van Rijssel
Science supervisor: dr. N. (Nynke) Smidt
Abstract:  

Even though a rare disease affects fewer than 1 in 2000 people, given the 6.000-8.000 different diagnoses, more than 1 million people are affected by a rare disease in the Netherlands.

Using health data of patients with a rare disease is crucial for improving care and treatment. The UMCG has 44 different centers of expertise, each specialised in its own field of rare diseases. In my project, I focus on creating an overview of how the different expertise centres register and share patient data, and the obstacles in (re)using patient data for care and research. This results in advice on how to improve (re)using rare disease patient data in the UMCG, based on literature research, and interviews with several involved parties, such as coordinators of the expertise centres, supporting staff, data stewards, and patient representatives.

In this project, I have gained valuable insight into the complex field of policy, data-sharing, different stakeholders, and the many developments currently happening in the field of healthcare digitalisation, and rare disease care and research developments. 

Feel free to join my presentation to gain more insight into the (re)use of rare disease patient data in the expertise centres, and how the UMCG can further improve in this aspect.

01 July 11:00 5159.0062

Master program: Medical Pharmaceutical Sciences
Keywords: data and biobank, strategic analysis. acute care research
Internship organization: Acutelines
Type of organization: Company
Workplace supervisor: prof. dr. H.R. (Hjalmar) Bouma
SBP supervisor: P.C. (Pieter) Vogelaar, MSc
Science supervisor: prof. dr. K. (Klaas) Poelstra
Abstract:  

Unlocking the Strategic Potential of Acutelines’ Data and Biobank 

High quality clinical data and biomaterial collections are essential for advancing research and innovation in acute care. Acutelines, a data and biobank infrastructure embedded within the emergency department of the UMCG, enables this data collection from the earliest stages of treatment. By capturing data and biomaterials throughout the acute care trajectory, Acutelines supports scientific research aimed at improving outcomes for acutely ill patients. 

Acutelines started five years ago and at this stage of its development, a clearer strategic focus has become essential to ensure sustainable growth, scalability, and effective collaboration. This project examines how Acutelines can strengthen its strategic position to support long term sustainability and maximize its societal and scientific impact.

The analysis explores both internal organizational factors and external opportunities that influence Acutelines’ development. Internal aspects such as governance, resources, and workflows, are examined alongside external trends, partnerships, and funding opportunities within the healthcare and research landscape. These insights are systematically integrated into strategic recommendations.

Preliminary findings highlight Acutelines’ strong technical infrastructure and its unique capability to collect high quality acute care data and biomaterials in a real world clinical setting. 

By analyzing strategic positioning, collaboration opportunities, and organizational processes, this project translates analytical insights into a well supported advisory report for Acutelines.

If you are interested in the outcomes of my project, I invite you to attend my presentation!

01 July 14:00 5159.0010

Master program: Medical Pharmaceutical Sciences
Keywords: Communication plan for disease modification potential of biologics
Internship organization: Sanofi
Type of organization: Company
Workplace supervisor: dr. M. (Marlous) Sneeboer
SBP supervisor: N. (Niels) Alberts-Visscher, MSc
Science supervisor: prof. dr. P. (Peter) Heeringa
Abstract:  

Translating advanced scientific concepts into clinical practice remains challenging, particularly when addressing emerging and insufficiently defined concepts such as disease modification. In chronic inflammatory conditions like eosinophilic esophagitis (EoE), there is currently no consensus on how disease modification or remission should be defined or evaluated in clinical practice.

An ongoing controlled clinical trial is investigating whether dupilumab, a monoclonal antibody targeting the shared IL‑4Rα receptor to inhibit IL‑4 and IL‑13 signaling, may exert disease‑modifying effects in EoE. EoE is a chronic, type 2 inflammatory disease of the esophagus, characterized by dysphagia, food impaction, and impaired quality of life, with potential for progressive fibrostenotic complications.

This project aims to explore the applicability of the concepts of remission and disease modification in EoE by: (1) reviewing how these concepts are defined in other type 2 inflammatory diseases, (2) developing preliminary working definitions tailored to EoE, and (3) identifying knowledge gaps in current clinical practice through expert interviews. The proposed definitions are subsequently refined and assessed for clinical relevance and practical feasibility.

The final outcome is the development of an evidence‑based strategic communication framework to support Sanofi Medical Affairs and Commercial teams in communicating clinical trial outcomes in a scientifically accurate, non‑promotional, and clinically meaningful manner. This work aims to facilitate clearer translation of complex clinical data into routine gastroenterology practice and contribute to a more consistent understanding of disease modification in EoE.

03 July 11:00 5159.0110

Master program: Biology
Keywords: Data-analysis, nature policy, National Ecological Network, Evidence-based policy
Internship organization: Provincie Drenthe
Type of organization: Policy organisation
Workplace supervisor: drs. M. (Maayke) Klaver
SBP supervisor:  drs. M.D.D. (Marlies) Westerhof
Science supervisor: prof. dr. G.S. (Sander) van Doorn
Abstract:  

The size and quality of nature areas in the Netherlands are declining and provinces carry part of the responsibility to counteract this. To this end, the provinces have various policy objectives, including the protection of the National Ecological Network. My internship is focused on how vegetation data can be applied to improve nature policies.  

To do this I research the Province’s policies and I perform literature research into the application of vegetation data. These two parts I will connect by performing a data-analysis focused on the quality of the heathlands in Drenthe. With the data-analysis I can assess if the theory is applicable in practice and identify the difficulties that arise using the vegetation data. I am also doing an external analysis of parties that are involved with the vegetation dataset that I look at and an internal analysis of the Province and its capabilities. Connecting all these parts I am able to integrate science and policy to deliver actionable advice. 

Science-based policy making is very important. However for this to work science and policy have to be connected, which creates big challenges at times. A part of the solution is to create a clear understanding of the policy question to connect the right scientific tools. 

Are you interested in my advice for the Province of Drenthe on how to do this? Visit my talk about the applicability of vegetation data in the nature policies of Drenthe on the 3rd of July in room 5159.0110 in the Energy Academy. 

02 July 11:00 5159.0267

Master program: Biomedical Sciences
Keywords: Market access strategy for a treatment of Kahler's disease
Internship organization: Johnson and Johnson
Type of organization: Company
Workplace supervisor: dr. S.(Sandra) Bovens
SBP supervisor: M.K. (Mart) van Genne, MSc
Science supervisor: prof. dr. G. (Geert) van den Bogaart
Abstract:  

Here is an overview of my internship within the Health Economics, Market Access & Reimbursement (HEMAR) department at Johnson & Johnson Innovative Medicine in Breda. Over the past months, my work has focused primarily on supporting the development of a pharmacotherapeutic report for Tecvayli® + Darzalex® (Tec‑D), a combination treatment consisting of a bispecific antibody and an anti‑CD38 monoclonal antibody, indicated for the treatment of relapsed/refractory multiple myeloma (RRMM). In my internship I will report scientific research on the disease area and treatment landscape, as well as my initial contributions to the market access strategy for Tec‑D in the Netherlands.

The scientific component of my work includes an analysis of RRMM epidemiology, current treatment pathways, unmet medical needs, and the clinical evidence supporting Tec‑D. On the market access side, I will have explored the structure of the Dutch reimbursement system, the role of the “sluis”(lock) for expensive medicines, and the key considerations that influence health technology assessments conducted by Zorginstituut Nederland. 

My preliminary findings highlight both the therapeutic value of Tec-D  and the challenges associated with securing reimbursement for innovative oncology treatments in the Netherlands. The pharmacotherapeutic report aims to support internal decision‑making and inform future interactions with external stakeholders. The second half of my internship will focus on completing the clinical value assessment. This means refining and strengthening the positioning of Tec‑D within the Dutch treatment landscape, and contributing to the broader HEMAR launch strategy.

01 July 14:00 5159.0114

Master program: Biomedical Sciences
Keywords: More nature in the living environment
Internship organization:  GGD Fryslân/Friese Preventieaanpak
Type of organization: Policy organisation
Workplace supervisor: drs. L. (Lilian) van den Berg
SBP supervisor:  drs. M.R. (Michiel) Berger
Science supervisor: prof. dr. G. (Gertjan) van Dijk
Abstract:  

The environment we live in is a key determinant of health. A healthy living environment promotes healthy behavior, while minimizing negative health impacts. Green (e.g. parks, gardens, tree streets) and blue (e.g. lakes, ponds) elements are increasingly recognized for their health benefits. However, these elements have yet to be structurally integrated into municipal policy plans in Friesland.

This project, carried out within the network organization Friese Preventie Aanpak (FPA), explores what the effects of green and blue elements in our living environment are. The research was conducted through a comprehensive literature review, expert interviews and the analysis of best practices. The goal of this project is to highlight the importance of green and blue elements in the living environment and provide practical guidance for municipalities to structurally integrate them into their policy plans, ultimately contributing to a healthier environment in Friesland.

Preliminary insights show that green and blue elements are not only important for promoting health but also contribute to stronger social cohesion and biodiversity, support climate adaptation, and make the living environment more pleasant and liveable.

If you are interested in the topic or want to know more about the project, feel welcome to attend my presentation!

03 July 11:00 5159.0291

Master program: Energy & Environmental Sciences
Keywords: Data-driven EV charger health indicators
Internship organization: Greenflux
Type of organization: Company
Workplace supervisor: K. (Kris) Borger, MSc
SBP supervisor: dr. G.A.H. (Gideon) Laugs
Science supervisor: dr. W. (Wided) Medjroubi
Abstract:  

The transition to low-emission mobility depends not only on the expansion of charging infrastructure, but also on its operational reliability. As electric vehicle (EV) uptake accelerates, charger uptime becomes a critical enabling condition for effective transport electrification. Infrastructure that is physically available but operationally unreliable can undermine user confidence, reduce asset utilization, and weaken the credibility of public charging systems.

This study investigates how operational charge station data can be used to develop indicators of EV charge station health that support more proactive maintenance and troubleshooting. The research is conducted in collaboration with GreenFlux and is positioned at the intersection of data analysis, operational decision-making, and sustainable mobility. The methodological approach is guided by data availability and combines some operational datasets from the EV chargers.

A central challenge in EV charging operations is not only collecting data, but translating operational signals into useful maintenance intelligence. Because charge station data are often fragmented and noisy, turning them into actionable support remains difficult in practice. By focusing on this challenge, the project contributes to both improved charger uptime and broader discussions on the role of data-driven operational intelligence in the energy transition.

Join this session to explore how charger data can be translated into more effective uptime management and what this means for the future of EV charging reliability.

02 July 10:00 5159.0179

Master program: Chemical Engineering
Keywords: Wastewater management for SCA 
Internship organization:  Svenska Cellulosa Aktiebolaget (SCA)
Type of organization:  Company
Workplace supervisor: H (Hannane) Akbari, MSc
SBP supervisor: M.J. (Maarten) van den Nieuwenhof-Schilstra, MSc
Science supervisor: prof. dr. P (Peter) Deuss
Abstract:  

SCA, Europe’s largest private forest owner, leverages its forest resources to produce timber, pulp, and paper. As part of its transition toward a low-carbon energy system, SCA is developing the Östrand Biorefinery project in collaboration with St1 to produce renewable fuels. This facility will utilize by-products from forestry and pulp operations, composed of sawdust and bark to generate sustainable fuels such as sustainable aviation fuel (SAF) and renewable naphtha.

This project focuses on the treatment of wastewater streams generated during this conversion process. These effluents exhibit a complex composition, including dissolved organic matter, nutrients, and residual process chemicals, requiring robust treatment to meet stringent discharge standards and enable water reuse.

Anaerobic biological treatment (ABT) is evaluated as the primary treatment technology, with emphasis on the removal of organic load and inhibitory compounds to facilitate integration of treated water into existing adjacent pulp mill infrastructure. Methane is formed in the process of ABT; although not the primary objective, its potential for valorization and its position within the biogas market are assessed.

Beyond technical performance, the study examines organizational feasibility within SCA’s strategic framework, including alignment with corporate sustainability objectives. A broader market and policy analysis is also conducted, encompassing the biogas sector, key stakeholders, and relevant regulatory drivers. These aspects are integrated to provide a comprehensive assessment of the technical, economic, and strategic viability of implementing ABT within the proposed biorefinery system.

01 July 11:00 5159.0291

Master program: Biomedical Sciences
Keywords: Synthetic drugs, public health, scientific uncertainty, policy advice, evidence-based policy
Internship organization:  Wetenschappelijke Raad voor het Regeringsbeleid
Type of organization: Policy organisation
Workplace supervisor: dr. R. (Ruth) Mampuys
SBP supervisor: J. (Jorien) Zevenberg, MSc
Science supervisor: prof. dr. J. D. A. (Jocelien) Olivier
Abstract:  

This project examines how scientific evidence on the health effects of synthetic drugs can be translated into responsible policy advice under conditions of uncertainty. Synthetic drugs represent a complex and rapidly evolving policy issue: new substances continue to emerge, while scientific knowledge about their health effects often remains incomplete or uneven. At the same time, health-related claims play a central role in public and political debates and are frequently used to support different policy perspectives.

The aim of this project is to support the Dutch Scientific Council for Government Policy (WRR) in formulating scientifically grounded and transparent advice on the health effects of synthetic drugs. To this end, the study combines a structured review of scientific literature with an analysis of how health-related claims are interpreted and used in policy and advisory contexts. Ten commonly used or emerging synthetic substances are analysed systematically, focusing on acute health effects, chronic health effects, and dependence potential.

The findings are synthesised in a comparative risk matrix that distinguishes between substances based on their health risks and the strength of the available evidence. In addition, the project identifies key areas of scientific uncertainty and examines how these uncertainties influence policy-relevant claims.

The project contributes to the WRR advisory process by clarifying which health-related statements can be supported with confidence, which require nuance, and where caution is necessary when formulating policy advice.

03 July 12:00 5159.0062

Master program: Marine Biology
Keywords: Monitoring, nature inclusive builing, water quality
Internship organization:  Dura Vermeer
Type of organization: Company
Workplace supervisor: I. (Isabelle) van der Wiel, MSc
SBP supervisor: dr. M.K. (Karin) de Boer
Science supervisor: prof. dr. L.L. (Laura) Govers
Abstract:  

In accelerating the transition toward a nature-inclusive built environment, the integration of artificial habitat enhancement structures, or ""fish hotels"", has emerged as a strategic response to tightening environmental regulations and societal demand for biodiversity. Dura Vermeer actively supports this transition, moving from traditional risk mitigation to a value-creation strategy that embeds ecological functionality directly into civil infrastructure.

To support this evolution, I have investigated the performance of fish hotels implemented along Amsterdam’s quay walls. Through an exploratory monitoring effort using various techniques, I assessed whether these structures successfully provide habitat for protected species, such as the river bullhead (Cottus perifretum) and the European eel (Anguilla anguilla), which are indicators of healthy ecosystems.

Beyond the ecological data, I analyzed the internal and external strategic capabilities of Dura Vermeer to exploit these ecological opportunities. My research identifies how the company can transform these habitats from experimental ""add-ons"" into reliable, commercially viable tools for project permitting. By providing empirical evidence of their performance, this project enables Dura Vermeer to navigate the upcoming stricter environmental requirements, ensuring that biodiversity becomes a standard, defensible component of their competitive tender applications.

I hope to see you at the SBP conference!

01 July 14:00 5159.0291

Master program: Biomedical Sciences
Keywords: Multimorbidity, Healthcare organisation, Healthcare accessibility, Integrated care, Healthcare optimisation
Internship organization:  Martini Ziekenhuis
Type of organization: Company
Workplace supervisor: dr. Ingrid Schuttert and D. (Dorine) van Staalduinen
SBP supervisor:  dr. M. (Marion) van Rijssel
Science supervisor: prof. dr. Barbara van Munster
Abstract:  

This internship focuses on improving the organization of care for patients with multimorbidity within a hospital setting. Given the fact that the population gets older  Multimorbidity, defined as the coexistence of multiple chronic conditions. This increase  presents challenges for healthcare systems due to growing complexity, fragmentation of care, and rising demand for coordination across specialties.

The project explores how care processes can be better structured in line with the principles of value-based healthcare, and the multimorbidity guidelines. A qualitative research approach was used, including semi-structured interviews with a wide range of healthcare professionals such as physicians, nurses, pharmacists, and policy staff. These interviews provided insight into current practices, bottlenecks, and opportunities for improvement in managing complex patient pathways.

Findings indicate that while clinical expertise is highly developed, care remains largely organized around individual disciplines. This can lead to fragmented decision-making, unclear ownership of overall patient management, and inefficiencies. At the same time, there is strong intrinsic motivation among professionals to collaborate more effectively and to better align care with patient goals.

Based on these insights, the project identifies key opportunities to improve integration, and support healthcare professionals in delivering more patient-centered and efficient care. The results contribute to ongoing efforts to make healthcare systems more sustainable while maintaining high-quality outcomes for complex patient populations.

01 July 14:00 5159.0062

Master program: Chemical Engineering
Keywords: Techno-economic assessment for heat integration
Internship organization:  Gasunie
Type of organization: Company
Workplace supervisor: ir. T. (Tanja) Takens
SBP supervisor:  M.J. (Maarten) van den Nieuwenhof-Schilstra, MSc
Science supervisor: dr. ir. A. (Arne) Hommes
Abstract:  

During the energy transition, energy security must be safeguarded while new energy carriers and sources are explored. Therefore, underground gas storages remain essential assets. However, in many cases these facilities are energy-intensive and offer clear opportunities for improving energy efficiency. This project investigated the technological and financial feasibility of reusing compression heat by means of a thermal buffer at one of Gasunie’s daughter companies: the fast-cycle natural gas storage EnergyStock Zuidwending.

Currently, promising opportunities exist for further integration of energy streams at the EnergyStock facility. This project aims to investigate whether a hot water buffer would offer a solution for employing compression heat prior to expansion to lower the necessary process energy. 

This research combines historical process data (2020-2025), thermodynamic modelling and scenario-based evaluations to assess the technical and economical feasibility of a hot water buffer under highly variable operating conditions. Multiple design scenarios are evaluated, focusing on buffer size, storage behaviour, efficiency and energy savings. All the while relevant stakeholders, regulatory considerations and financial aspects are not lost out of sight. 

The results of said research feed into a broadly substantiated business case which combines energy efficiency gains, operational flexibility and financial viability into an advice on how to progress. By potentially reducing fuel gas consumption and thereby associated CO2 emissions, the investigated approach aims to support Gasunie’s and EnergyStock’s ISO 50001 objectives and demonstrates how energy reliability and improved sustainability can co-exist in an energy-intensive industry. 

Are you interested in the findings of this project? Join the presentation at the SBP conference on 1 July at 14.00!

02 July 10:00 5159.0010

Master program: Medical Pharmaceutical Sciences, Farmacie
Keywords: Optimization patient referrals, uncontrolled CRS, North-Europe
Internship organization:  Sanofi B.V.
Type of organization: Company
Workplace supervisor: dr. A. (Anna) Ekman
SBP supervisor:  J. (Jorien) Zevenberg, MSc
Science supervisor: prof. dr. R.(Reinoud) Gosens
Abstract:  

Chronic rhinosinusitis (CRS), including CRS with nasal polyps, is a prevalent chronic condition that substantially affects quality of life and healthcare utilization across Northern Europe. Although clinical guidelines for CRS management are well established, many patients still reach specialist care late, indicating persistent challenges at the interface between primary and secondary care. This project examines how CRS referral pathways function in real‑world practice and identifies critical gaps that contribute to delayed or suboptimal care.

Using a qualitative, exploratory design, the study conducts a structured gap analysis of referral practices between primary and secondary care. Data were collected through semi‑structured interviews with general practitioners, ENT specialists, rhinologists, medical advisors, and healthcare experts across multiple Northern European settings. The analysis focuses on how guidelines are interpreted in daily practice, how referral urgency is assessed, and how decision‑making is influenced by clinical uncertainty, patient expectations, and system‑level constraints.

Preliminary findings suggest that delays in referral speed are not always perceived as clinically significant, despite their impact on disease progression and patient outcomes. In addition, patients appear to exert substantial influence at the primary care level, which may contribute to repeated or prolonged use of antibiotics and systemic corticosteroids before specialist referral. Variability in primary care support structures and educational initiatives further contributes to inconsistent management approaches.

The project translates these insights into policy‑oriented recommendations aimed at improving early recognition, strengthening primary care support, and promoting responsible medication use. This research is relevant to policymakers, healthcare professionals, and life‑science stakeholders interested in optimizing chronic disease pathways. Attendees are invited to join the presentation to explore how gap‑driven policy design can better support primary healthcare providers.

02 July 14:00 5159.0010

Master program: Biomedical Sciences
Keywords: Supporting primary care in secondary progressive MS
Internship organization:  Sanofi B.V.
Type of organization: Company
Workplace supervisor: dr. T. (Troy) Schoenmaker
SBP supervisor: P.C. (Pieter) Vogelaar, MSc
Science supervisor: prof. dr. E. (Eddy) van der Zee
Abstract:  

From Guidelines to Practice: Challenges and Opportunities in the Care of People with MS - Exploring opportunities to strengthen the role of primary care in MS, with a focus on Secondary Progressive MS

Multiple sclerosis (MS) is a complex and progressive neurological condition. As the disease advances, treatment options become more limited, and care may gradually shift from specialised secondary care to primary care. However, clear guidance for general practitioners and structured communication with secondary care are often lacking.

This project explores how primary care can be better supported in the management of MS, with a focus on secondary progressive multiple sclerosis (SPMS) in the Netherlands. An exploratory qualitative approach was used, combining analysis of care pathways and guidelines with interviews among healthcare professionals from both primary and secondary care.

Preliminary findings suggest that general practitioners encounter too few MS patients to develop routine, leading to uncertainty in managing progressive disease. Many express a need for clearer role delineation and practical guidance. While some value concise guidelines, others prefer a low-threshold point of contact, such as an MS nurse, when dealing with complex cases. The need for additional education varies.

These findings highlight that improving MS care is not only a clinical challenge, but also an organisational one, requiring clearer collaboration and support across care settings.

02 July 11:00 5159.0110

Master program: Biomedical Sciences
Keywords: Chronobiology, Chronotherapy, Circadian rhythms, Healthcare implementation, Translational medicine
Internship organization:  Chrono@Work
Type of organization: Company
Workplace supervisor: dr. M.C.M. (Marijke) Gordijn
SBP supervisor:  drs. M.D.D. (Marlies) Westerhof
Science supervisor: prof. dr. R.A. (Roelof) Hut
Abstract:  

Circadian rhythms regulate a wide range of physiological and behavioural processes, including sleep, cognition, and metabolism. Chronotherapy builds on this by aligning interventions with the biological clock, such as optimising treatment timing, or by shifting circadian rhythms through interventions such as light therapy, melatonin treatment, and behavioural adjustment. Although scientific evidence on chronobiology and chronotherapy has expanded rapidly, translation into routine healthcare practice remains limited. This creates a gap between what is scientifically possible and what is structurally embedded within the Dutch healthcare system.

To address this gap, insights from chronobiological science, healthcare practice, and the Dutch policy and reimbursement landscape are integrated to assess where and how circadian approaches can add value within existing healthcare structures.

Scientific evidence shows that circadian approaches are most immediately applicable in circadian rhythm sleep wake disorders, where diagnosing and treatment support effective patient care. In other domains such as oncology, circadian insights can improve care, but require careful positioning within existing clinical pathways and collaboration with established disciplines. Broader implementation therefore depends both on further scientific validation and on effective integration into existing healthcare systems.

This project provides a structured framework for embedding circadian science into healthcare practice and clarifies under which conditions chronotherapy can be translated into real-world impact. 

03 July 11:00 5159.0062

Master program: Biology
Keywords: Reducing water pollution by pharmaceutical residues
Internship organization: TCNN
Type of organization: Foundation (Stichting)
Workplace supervisor: dr. Erika Brattinga-Róth
SBP supervisor: dr. M.K. (Karin) de Boer
Science supervisor: prof. dr. G.J.W. (Gert-Jan) Euverink
Abstract:  

PREWAPHARM is an Interreg NWE project aimed at the environmental problem of pharmaceuticals in water. 18 partners from 6 countries have joined forces in this project, with TCNN being the lead partner to reduce the complex problem of water pollution by pharmaceuticals. Pharmaceutical residues threaten ecosystems, and possibly even our drinking water supply in the future. The main focus of the internship project was the development of a transnational strategy and its translation into regional action plans to mitigate this problem in the north of the Netherlands. 

To ensure effectivity, and in order to gather information, dialogues with the organisations that eventually could implement this strategy were held. These include a broad range of essential stakeholders such as provinces, water authorities, hospitals and pharmacists. The dialogues were held based on a standardized questionnaire. Literature research was also done on an analysis of what legislation and policies are already in place. In addition, a symposium was organized in which stakeholders could engage in direct discussion with each other on key points.

The internship project led to some interesting results, including a better understanding of legislation already in place. Obstacles that currently limit progress have also been described. Furthermore, the project led to insights into what each stakeholder needs in order to take significant steps. 

This internship project helps to integrate scientific knowledge with the practical strategic environments in which these insights could possibly be applied. I look forward to sharing my findings. 

01 July 12:00 5159.0114

Master program: Biomedical Sciences
Keywords: Healthcare, Movement, Exercise, Mental health, Public health
Internship organization:  GGD IJsselland
Type of organization: Policy organisation
Workplace supervisor: dr. T. (Tessa) Overmars
SBP supervisor:  drs. M.R. (Michiel) Berger
Science supervisor: prof. dr. G. (Gertjan) van Dijk
Abstract:  

In recent years, there has been growing attention for the relationship between physical activity and well being in children. At the same time, regional data shows that many children do not meet the recommended levels of daily physical activity. This raises the question of how children themselves experience being active and how this connects to how they feel.

This project explores the experiences of children in the final year of primary school. It combines an analysis of regional data from the Kindermonitor of GGD IJsselland with group conversations with children. By doing this, the study not only looks at patterns in behaviour, but also tries to understand the meaning behind these patterns from the perspective of children.

The first findings suggest that physical activity is not mainly seen as something related to health. Instead, children talk about fun, social interaction, and feeling confident. Differences between boys and girls also appear, both in how often they are active and in how they experience it.

This study shows the value of combining data with children’s own perspectives. It offers insights that can help GGD IJsselland and other stakeholders develop policies and interventions that better fit the everyday lives of children.

The presentation will explore these findings and reflect on what they could mean in practice.

03 July 10:00 5159.0291

Master program: Biomedical Sciences
Keywords: AI validation on lung CT
Internship organization: institute for DiagNostic Accuracy (iDNA)
Type of organization: Company
Workplace supervisor: K. (Katerina) Togka, MSc
SBP supervisor:  M.K. (Mart) van Genne, MSc
Science supervisor: prof. dr. A. (Anke) van den Berg
Abstract:  

Lung cancer is the leading cause of cancer-related mortality worldwide. A key challenge in relation to lung cancer is that it is often asymptomatic, which means that many individuals are diagnosed only at a later stage. To address this, the institute for DiagNostic Accuracy (iDNA) has conducted multiple clinical trials aimed at identifying lung cancer at an earlier stage, although this screening approach has not yet been standardised across the EU. At the same time, the introduction of additional screening increases the workload of radiologists. To help reduce this burden, the use of artificial intelligence (AI) is envisioned as an additional reader within the diagnostic process. Before such an AI can be implemented in a real clinical setting, however, it must first be validated. In this context, iDNA can present its obtained lung CT scan data to AI companies in order to validate their AI. iDNA intended to offer this data to AI companies in the form of a platform. The objective of this research was to identify all information relevant to the launch and market entry of this platform. To do so, research was first conducted into the fields of lung cancer, AI,

the regulatory policies affecting the platform, and the needs of both iDNA and AI companies. These insights were subsequently combined to develop a pricing model and a strategy to support iDNA in entering the market with its newly developed platform.

03 July 11:00 5159.0291

Master program: Biomedical Sciences
Keywords: Market scalability for lung cancer screening management software
Internship organization:  institute for DiagNostic Accuracy (iDNA)
Type of organization: Company
Workplace supervisor: J. (Jurgen) Knol, MSc
SBP supervisor:  dr. M. (Marion) van Rijssel
Science supervisor: prof. dr. J.H.M. (Anke) van den Berg
Abstract:  

Lung cancer screening is expanding globally and nearing full rollout in England, creating large volumes of data and a growing need for scalable workflow solutions. Nelson+ has developed a data/participant management system that supports the full screening pathway, from patient invitation to follow-up scheduling. To capture this growing market, Nelson+ must address challenges related to scalability.

This study combines a literature review, internal documentation, and interviews to develop a comprehensive understanding of the product and organization. The McKinsey 7S framework is applied to assess the organization, while the value proposition framework evaluates customer benefits. Interviews with end users indicate high satisfaction with the system, with no significant unused features, shifting the focus toward the human aspects of scaling, particularly the onboarding and product implementation process.

Further analysis of implementation is conducted through internal insights and interviews, complemented by external interviews with comparable organizations to identify best practices in scaling similar products. The points of improvements will be evaluated using the SAFe framework to select solutions which best suit their internal capabilities and values.

This project aims to provide recommendations for scaling Nelson+ while maintaining client satisfaction and operational effectiveness. If possible, Nelson+ can be used to make the screening process more efficient and safe, allowing for more lung cancers to be detected in earlier stages and improve patient outcomes.

If you are interested in how a company can be scaled safely and effectively or have your own ideas, feel free to join the discussion at the SBP conference!